Motexafin gadolinium enhances the efficacy of aminolevulinic acid mediated-photodynamic therapy in human glioma spheroids.
Photodynamic therapy (PDT) has been investigated as a postoperative treatment in patients with high grade gliomas. The purpose of this in vitro investigation was to determine whether motexafin gadolinium (MGd), a known radiation sensitizer, could potentiate the effects of 5-aminolevulinic acid (ALA)-PDT. Human glioma (ACBT) spheroids (250 microm diameter) were incubated in 5-aminolevulinic acid (ALA) with and without MGd and irradiated with 635 nm light for a total light fluence of 6, 12, or 18 J cm(-2) delivered at a fluence rate of 5 mW cm(-2). Spheroid growth was monitored for a period of 4 weeks following each treatment. In another set of experiments, 400-500 microm diameter ACBT spheroids were implanted into a gel collagen matrix and subjected to ALA-PDT (fluence: 3 or 6 J cm(-2)), MGd, or a combination of ALA-PDT and MGd. The migration distance of surviving glioma cells in each treatment group was recorded over a 5-day period. The results showed that MGd interacted with PDT in a synergistic manner resulting in greater cytotoxicity than that achievable with either treatment modality alone. The degree of synergism was shown to increase with increasing light fluence. At the highest light fluence investigated (18 J cm(-2)), the percentage of spheroids demonstrating growth 4 weeks following exposure to MGd, ALA-PDT, or MGd + ALA-PDT was 100%, 75%, and 15%, respectively. The results of cell migration studies revealed that the combination of PDT and MGd produced a significant inhibitory effect on glioma cell migration: the addition of MGd resulted in an approximately three times reduction in migration distance compared with PDT alone. Overall, the results suggest that MGd can potentiate both the cytotoxic and migration inhibitory effects of ALA-PDT and hence, this combined therapeutic approach has the potential to extend treatment volumes in patients with malignant gliomas.
Madsen
Steen J
SJ
Department of Health Physics, University of Nevada, Las Vegas, NV 89154-3037, USA. steen.madsen@unlv.edu
Mathews
Marlon S
MS
Angell-Petersen
Even
E
Sun
Chung-Ho
CH
Vo
Van
V
Sanchez
Rogelio
R
Hirschberg
Henry
H
D000622:Aminolevulinic Acid / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D004307:Dose-Response Relationship, Radiation; D004357:Drug Synergism; D004996:Ethidium / Q000031:analogs & derivatives; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D008665:Metalloporphyrins / Q000627:therapeutic use*; D009361:Neoplasm Invasiveness; D010778:Photochemotherapy; D018874:Spheroids, Cellular / Q000187:drug effects* / Q000528:radiation effects; D013997:Time Factors
D000970:Antineoplastic Agents; D008665:Metalloporphyrins; C018533:ethidium homodimer; C437683:motexafin gadolinium; D000622:Aminolevulinic Acid; D004996:Ethidium
J Neurooncol. 2002 Jan;56(2):149-58
11995816
Lasers Surg Med. 1986;6(3):318-22
2942742
J Environ Pathol Toxicol Oncol. 2007;26(2):149-55
17725541
Nat Rev Cancer. 2003 Jul;3(7):489-501
12835669
J Clin Oncol. 2001 Apr 1;19(7):2074-83
11283141
J Photochem Photobiol B. 1998 Sep;45(2-3):160-9
9868806
Biochem Pharmacol. 2000 Apr 1;59(7):733-9
10718331
J Clin Oncol. 2003 Jul 1;21(13):2529-36
12829672
Curr Neurol Neurosci Rep. 2005 May;5(3):198-206
15865885
J Pharmacol Exp Ther. 2001 Jun;297(3):888-94
11356908
Photochem Photobiol. 1996 Jul;64(1):163-7
8787009
Acta Neurochir (Wien). 1998;140(5):503-12; discussion 512-3
9728253
Cancer Biochem Biophys. 1976 May;1(4):187-95
975020
J Clin Oncol. 2004 Jan 1;22(1):157-65
14701778
J Clin Oncol. 2002 Aug 15;20(16):3445-53
12177105
Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1570-6
15050338
Anticancer Res. 1997 Nov-Dec;17(6B):4145-9
9428348
Neurosurgery. 1998 Mar;42(3):518-25; discussion 525-6
9526986
Lasers Surg Med. 2006 Jun;38(5):540-8
16392143
Int J Cancer. 1996 Jul 17;67(2):275-82
8760599
J Neurooncol. 2006 Mar;77(1):95-103
16547607
Clin Cancer Res. 1999 Apr;5(4):739-45
10213207
Photochem Photobiol. 2002 Oct;76(4):411-6
12405149
J Clin Laser Med Surg. 1998 Apr;16(2):81-91
9663099
Adv Exp Med Biol. 1983;160:63-76
6220579
J Biomed Opt. 2007 Jan-Feb;12(1):014003
17343478
Photochem Photobiol. 2004 Jul-Aug;80:22-30
15339204
Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1405-9
2542195
Expert Rev Anticancer Ther. 2004 Dec;4(6):981-9
15606327
Clin Cancer Res. 2006 Jan 1;12(1):206-13
16397044
Photochem Photobiol. 1993 Dec;58(6):895-900
8310013
Mol Med. 1998 Jan;4(1):40-5
9513188
Neurosurgery. 1995 Aug;37(2):294-301; discussion 301-2
7477782
Lasers Med Sci. 2008 Oct;23(4):361-7
17926079
Lasers Surg Med. 2006 Dec;38(10):939-45
17163479
J Neurooncol. 2003 May;62(3):243-50
12777075
Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):981-9
10571206
Minim Invasive Neurosurg. 2007 Dec;50(6):318-23
18210352
Photochem Photobiol. 1985 Aug;42(2):153-62
4048297
Br J Cancer. 1994 Jul;70(1):21-8
8018536
Radiology. 1999 Sep;212(3):755-9
10478243
Oncogene. 2001 Oct 11;20(46):6669-78
11709701
Semin Cancer Biol. 2006 Dec;16(6):466-76
17112739
Photochem Photobiol. 2000 Jul;72(1):128-34
10911737
Phys Med Biol. 1986 Nov;31(11):1295-7
3786415
Lasers Surg Med. 2007 Jun;39(5):386-93
17565715
J Neurosurg. 1995 Apr;82(4):615-22
7897524
J Neurooncol. 2004 Dec;70(3):289-99
15662970
Br J Cancer. 1998 Sep;78(6):733-8
9743291
Lasers Surg Med. 2001;29(5):406-12
11891728
J Neurosurg. 2000 Dec;93(6):1003-13
11117842
Can J Neurol Sci. 1997 Feb;24(1):3-15
9043741
Curr Opin Oncol. 2004 Nov;16(6):576-80
15627019
J Environ Pathol Toxicol Oncol. 2006;25(1-2):261-79
16566723
Exp Neurol. 1983 Feb;79(2):564-8
6822280
Br J Cancer. 2000 Oct;83(8):1110-7
10993661